display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - triple negative
es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)es-BC - TNBC - NA - all populationes-BC - TNBC - NA - PDL1 positive
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus carboplatin plus nab-paclitaxel NeoTrip Michel Angelo
atezolizumab plus carboplatin plus paclitaxel NCI 10013 NCI 10013
atezolizumab plus nab-paclitaxel IMpassion-031 ... IMpassion-031 ...
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide IMpassion-031 ...
atezolizumab plus paclitaxel ALEXANDRA/IMpassion-030
avelumab based treatment
avelumab alone A-Brave A-Brave Stratum A
durvalumab based treatment
durvalumab alone GeparNuevo
pembrolizumab based treatment
pembrolizumab plus SoC KEYNOTE-522

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons